Compoundeer Logo
COMPOUNDEER
Uncovering Potential
RankingCompaniesDCF
EYPT Logo

Eyepoint Pharmaceuticals, Inc.

EYPT

Laboratory Analytical Instruments

Mkt Cap

$1.089B

PE

-10.87

Debt

$0

Cash

$133.2M

EV

$955.4M

FCF

$9.211M

Market Cap

$1.089B

P/E Ratio

-10.87

Debt

$0

Cash

$133.2M

EV

$955.4M

FCF

$9.211M
Charts data: {"Earnings":[{"time":"2014-06-29","value":-13355000},{"time":"2015-06-29","value":6347000},{"time":"2016-06-29","value":-21547000},{"time":"2017-06-29","value":-18485000},{"time":"2019-12-30","value":-56793000},{"time":"2020-12-30","value":-45394000},{"time":"2021-12-30","value":-58417000},{"time":"2022-12-30","value":-102254000}],"Sales":[{"time":"2014-06-29","value":3473000},{"time":"2015-06-29","value":26565000},{"time":"2016-06-29","value":1620000},{"time":"2017-06-29","value":7539000},{"time":"2019-12-30","value":20365000},{"time":"2020-12-30","value":34437000},{"time":"2021-12-30","value":36939000},{"time":"2022-12-30","value":41404000}],"Net Margins":[{"time":"2014-06-29","value":-3.8453786351857184},{"time":"2015-06-29","value":0.23892339544513458},{"time":"2016-06-29","value":-13.300617283950617},{"time":"2017-06-29","value":-2.451916699827563},{"time":"2019-12-30","value":-2.7887552172845567},{"time":"2020-12-30","value":-1.3181752185149693},{"time":"2021-12-30","value":-1.5814450851403665},{"time":"2022-12-30","value":-2.469664766689209}],"Assets":[{"time":"2014-06-29","value":22671000},{"time":"2015-06-29","value":32367000},{"time":"2016-06-29","value":31619000},{"time":"2017-06-29","value":18677000},{"time":"2019-12-30","value":72971000},{"time":"2020-12-30","value":91717000},{"time":"2021-12-30","value":263372000},{"time":"2022-12-30","value":180356000}],"Stockholders Equity":[{"time":"2014-06-29","value":14924000},{"time":"2015-06-29","value":23368000},{"time":"2016-06-29","value":20881000},{"time":"2017-06-29","value":13336000},{"time":"2019-12-30","value":8330000},{"time":"2020-12-30","value":18541000},{"time":"2021-12-30","value":184380000},{"time":"2022-12-30","value":96368000}],"ROE":[{"time":"2014-06-29","value":-0.894867327794157},{"time":"2015-06-29","value":0.2716107497432386},{"time":"2016-06-29","value":-1.0318950241846654},{"time":"2017-06-29","value":-1.3860977804439112},{"time":"2019-12-30","value":-6.817887154861944},{"time":"2020-12-30","value":-2.4483037592362873},{"time":"2021-12-30","value":-0.31682937411866796},{"time":"2022-12-30","value":-1.0610783662626597}],"ROA":[{"time":"2014-06-29","value":-0.5948127563848088},{"time":"2015-06-29","value":0.19906077177372014},{"time":"2016-06-29","value":-0.6863594674088365},{"time":"2017-06-29","value":-0.9897199764416127},{"time":"2019-12-30","value":-0.6558906963040112},{"time":"2020-12-30","value":-0.40657675240140867},{"time":"2021-12-30","value":-0.20987804322403292},{"time":"2022-12-30","value":-0.552446272926878}]}

EyePoint Pharmaceuticals, Inc. focuses on developing and commercializing therapeutics to help improve the lives of patients with serious eye disorders. The company's pipeline leverages its proprietary erodible Durasert E technology for sustained intraocular drug delivery, including EYP-1901, an investigational sustained delivery intravitreal anti-VEGF treatment, which is in Phase 2 clinical trials. The company was formerly known as pSivida Corp. and changed its name to EyePoint Pharmaceuticals, Inc. in March 2018. EyePoint Pharmaceuticals, Inc. was incorporated in 1987 and is headquartered in Watertown, Massachusetts.

Sector

  • A Logo

    A

  • AVTR Logo

    AVTR

  • BIO Logo

    BIO

  • BRKR Logo

    BRKR

  • CTKB Logo

    CTKB

  • ILMN Logo

    ILMN

  • MTD Logo

    MTD

  • NAUT Logo

    NAUT

  • PACB Logo

    PACB

  • QTRX Logo

    QTRX

Growth

%

%

Discount

%

%

Multiple

g\r+10%+11%+12%+13%+14%
0%109887
+1%1110988
+2%13111098
+3%141311109
+4%1714121110
Years012345678910TV
FCF$9.211M$9.252M$9.293M$9.334M$9.375M$9.416M$9.458M$9.499M$9.541M$9.583M$9.626M$96.26M
DCF$8.045M$7.026M$6.137M$5.36M$4.681M$4.089M$3.571M$3.119M$2.724M$2.379M$23.79M
Value$70.93M

In the chart Earnings are multiplied by this value.

Earnings Growth -49%
Earnings Stability -28%


Competitiveness and MOAT

High margins render the company resilient under dire circumstances, hence able to drive competitors out or acquire them. ROE and ROA measure the average flow generated by each invested dollar. Their marginal value is a forecast of future growth, and it is considered by Buffett and Munger the most important single indicator.

Years06-201406-201506-201606-201712-201912-202012-202112-2022TTM
Net Margin-380%24%-1.3K%-250%-280%-130%-160%-250%-240%
ROA-59%20%-69%-99%-66%-41%-21%-55%-64%
ROE-89%27%-100%-140%-680%-240%-32%-110%-170%

What is the average Net Margin?

The average Net Margin over the past 5 years is -398.51%.

What is the trend of Net Margin?

The trend of Net Margin over the past 5 years is +166.39%.

What is the average Return on Assets (ROA)?

The average ROA over the past 5 years is -58.35%.

What is the trend of Return on Assets (ROA)?

The trend of ROA over the past 5 years is +9.31%.

What is the average Return on Equity (ROE)?

The average ROE over the past 5 years is -217.7%.

What is the trend of Return on Equity (ROE)?

The trend of ROE over the past 5 years is +21.23%.


Safety & Stabiliy

Being debt the number one cause of investment losses and company death, the ratio Debt/FCF is of utmost importance to guarantee safety. On the other hand the Graham’s stability measures the drawdown of earnings, hence indicating the reliability of the flow generated by the company.

Years06-201406-201506-201606-201712-201912-202012-202112-2022TTM
Debt FCF---0.00-0.83-2.57-0.73-0.600.00
Debt Equity---0.005.672.050.200.420.00
MIN
Graham Stability---------

What is the Debt/FCF?

The Debt/FCF trailing twelve month is 0.00.

What is the trend of Debt/FCF?

The trend of Debt/FCF over the past 5 years is -0.11.

What is the Graham’s Stability?

Graham’s Stability measure stands at -.


Growth

Growth can be dangerous when forecasting, simply projecting the current growth is in general wrong. A company passes through multiple phases, from being young and unprofitable, to the first periods of profitability and high growth, until it arrives at a period of regime with limited growth. Identifying in which phase the company is in may help forecasting.

Years06-201406-201612-201912-2021Trend
Revenue42%91%27%12%-73%
Net Income-----
Stockholders Equity31%36%130%-48%59%
FCF-----

What is the 5 year Revenue CAGR?

The Revenue CAGR over the past 5 years is +91.21%.

What is the trend of Revenue growth?

The trend of Revenue growth rate over the past 5 years is -73.3%.

What is the 5 year Earnings CAGR?

The Earnings CAGR over the past 5 years is +36.54%.

What is the trend of Earnings growth?

The trend of Earnings growth rate over the past 5 years is -.

What is the 5 year Equity CAGR?

The Equity CAGR over the past 5 years is +35.78%.

What is the trend of Equity growth?

The trend of Equity growth rate over the past 5 years is +59.14%.

What is the 5 year FCF CAGR?

The FCF CAGR over the past 5 years is +32.52%.

What is the trend of FCF growth?

The trend of FCF growth rate over the past 5 years is -.